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Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the aetiological 
agent of coronavirus disease 2019 (COVID-19), an emerging respiratory infection 
caused by the introduction of a novel coronavirus into humans late in 2019 (first 
detected in Hubei province, China). As of 18 September 2020, SARS-CoV-2 has spread 
to 215 countries, has infected more than 30 million people and has caused more than 
950,000 deaths. As humans do not have pre-existing immunity to SARS-CoV-2, there 
is an urgent need to develop therapeutic agents and vaccines to mitigate the current 
pandemic and to prevent the re-emergence of COVID-19. In February 2020, the World 
Health Organization (WHO) assembled an international panel to develop animal 
models for COVID-19 to accelerate the testing of vaccines and therapeutic agents. 
Here we summarize the findings to date and provides relevant information for 
preclinical testing of vaccine candidates and therapeutic agents for COVID-19.
Although there are discrepancies in the estimated case-to-fatality ratio 
of COVID-19 in humans, it is clear that severity is age-stratified and that 
the case-to-fatality ratio in patients over 65 years of age is probably 
higher than 1%1. Infection with SARS-CoV-2 is initially characterized by 
a range of mild symptoms, including fever, cough, dyspnoea and myal-
gia2. In part, these symptoms are caused by the capacity of SARS-CoV-2 
to replicate efficiently in the upper respiratory tract. Although most 
individuals subsequently resolve the infection, the disease may also 
progress to severe pneumonia. In severe cases, bilateral lung involve-
ment with ground-glass opacities is the most common finding in com-
puted tomography scanning of the chest. Disease progression can then 
involve acute respiratory distress syndrome and—in some cases—an 
inflammatory syndrome that resembles septic shock. Histological 
examination of the lungs of patients showed bilateral diffuse alveolar 
damage, pulmonary oedema and formation of hyaline membranes3. 
COVID-19 is also characterized by damage to additional organ systems, 
associated with coagulopathy and characterized by elevated fibrino-
gen and D-dimer levels that indicate increased thrombus generation 
and fibrinolysis4. Individuals at a higher risk of developing severe 
COVID-19 include those with underlying conditions, such as obesity, 
diabetes, hypertension, chronic respiratory disease and cardiovas-
cular disease1.
Through the ‘Solidarity’ trials, the WHO has launched a global cam-
paign to test therapeutic agents and vaccines on an unprecedented 
scale5. To test these and other potential medical countermeasures, it is 
imperative to identify animal models for COVID-19 that provide measur-
able readouts for potential interventions and that use representative 
virus isolates6. To this end, the WHO Research & Development Blueprint 
Team established an ad hoc expert working group focused on COVID-
19 modelling (COM), known as WHO-COM. In this Review, we provide 
a summary of the current literature on animal models for COVID-19 
(Table 1, Supplementary Table 1) that includes studies generated by 
the WHO-COM group since February 2020, which we hope will serve to 
facilitate further preclinical analysis of vaccines and therapeutic agents.
Mouse models
The main impediment to the infection of mouse (Mus musculus) 
cells with SARS-CoV-2 is the lack of appropriate receptors to initi-
ate viral infection. SARS-CoV-2—as severe acute respiratory syn-
drome coronavirus (SARS-CoV)—uses the cellular surface protein 
angiotensin-converting enzyme 2 (ACE2) to bind and enter cells, and 
mouse ACE2 does not effectively bind the viral spike protein7. Several 
strategies have been developed to solve this problem, as detailed here.
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Virus adaptation to mouse ACE2
The spike protein of SARS-CoV-2 can be modified to gain effective 
binding to mouse ACE2. One strategy to achieve this modification is 
the sequential passaging of SARS-CoV-2 in mouse lung tissue8. This 
method is successful because populations of RNA viruses consist of a 
swarm of closely related viral quasispecies. Rare viruses in the swarm 
that contain mutations in the spike protein that increase their bind-
ing affinity to mouse ACE2 are expected to be selected, owing to their 
higher levels of replication in mouse lungs. Alternatively, SARS-CoV-2 
can be adapted to infect mouse cells by using reverse genetics to modify 
the receptor-binding domain of the virus so that it can infect mouse 
cells via the mouse ACE2 protein. Using two approaches, mice have 
been sensitized for infection but have developed only very mild dis-
ease9. It is likely that additional efforts aimed at adapting SARS-CoV-2 
to mice will result in the outgrowth of additional virus variants that can 
cause more severe disease. These mice will then be useful for patho-
genesis studies, and for studies of antiviral agents and vaccines. One 
potential caveat is that the mutations in the SARS-CoV-2 spike pro-
tein that enhance affinity for the mouse ACE2 receptors are located 
in the receptor-binding domain, which is the primary target for the 
neutralizing antibody response. These mutations could thus result 
in a monoclonal antibody that neutralizes the wild-type virus being 
falsely considered as non-neutralizing.
Expression of human ACE2 in genetically modified mice
Another approach to infect mice with SARS-CoV-2 consists of modify-
ing the mice to express human ACE2. There are currently three trans-
genic mouse models, in which human ACE2 is under the expression 
of a tissue-specific promoter (for example, the Krt18 promoter for 
epithelial cells10; K18-hACE2 mice), a universal promoter (cytomeg-
alovirus enhancer followed by the chicken β-actin promoter11) or the 
endogenous mouse Ace2 promoter12. All of these mice are susceptible to 
infection by SARS-CoV-2, but differences in their expression of human 
ACE2 result in a pathogenic range of mild to lethal disease. With the 
exception of the model in which human ACE2 is controlled by the Ace2 
promoter, mice develop encephalitis after infection with SARS-CoV13 
or SARS-CoV-214 in these models. However, while SARS-CoV infection of 
K18-hACE2 mice results in highly lethal encephalitis, the neurological 
infection caused by SARS-CoV-2 infection in these mice is less severe. 
Some mice appear to succumb to severe pneumonia, at times at which 
the brain infection is not substantial15. Notably, these mice develop 
evidence of thrombosis and anosmia after infection with SARS-CoV-2 
and have been used for studies of the innate and T cell responses16. Mice 
develop severe disease after infection with SARS-CoV-2 in these models, 
and therefore may provide proof-of-concept data to support vaccine 
and therapeutic efficacy and may be useful for pathogenesis studies.
An alternative approach that mirrors the tissue-specific expression 
of human ACE2 is to substitute the Ace2 gene with the human ACE2 
gene. Similar models that express human dipeptidyl peptidase 4—
the receptor used by Middle East respiratory syndrome coronavirus 
(MERS-CoV)—have successfully been developed17–19. One mouse model 
humanized with human ACE2 has been reported, and supports repli-
cation of SARS-CoV-2 in respiratory and brain tissues (although mice 
do not develop severe disease)20. However, more severe disease is 
expected to occur in human ACE2 knock-in mice if virus is passaged 
serially through mouse lungs. Overall, these mice will probably be 
very useful models of human disease—especially if combined with 
viral adaptation that increases the virulence of SARS-CoV-2 in mice.
Finally, instead of permanent genetic modification, it is also possible 
to generate mice that are susceptible to infection with SARS-CoV-2 by 
sensitizing the respiratory tract of these mice to SARS-CoV-2 replica-
tion through transduction with adenovirus or adeno-associated virus 
that expresses human ACE2 (Ad5-hACE2 or AAV-hACE2, respectively). 
This system, which was pioneered in studies of MERS21, allows the tran-
sient replication of SARS-CoV-2 in the lungs of mice for several days 
until immune clearance, and it has the advantage that it can be applied 
quickly to different strains of mice. Upon infection with SARS-CoV-2, 
mice transduced with Ad5-hACE2 develop a widespread infection of 
the lungs and histopathological changes that are consistent with viral 
pneumonia. These mice developed clinical disease, as characterized by 
changes in body scoring (hunching) and weight loss. Virus is generally 
cleared by seven days after infection, although not in some immuno-
compromised mice14,22. Mice sensitized via AAV-hACE2 delivery are also 
susceptible to infection with SARS-CoV-2, but virus replication seems 
to be lower than in mice transduced with Ad5-hACE223. Mice sensitized 
with Ad5-hACE2 or AAV-hACE2 are useful for evaluating vaccines and 
antiviral therapies, as well identifying SARS-CoV-2-specific antibody 
and T cell epitopes. A limitation with these mice—as well as in some of 
the transgenic mice expressing human ACE2—is that human ACE2 is 
expressed ectopically, which may change the tissue or cellular tropism 
of the virus.
Other mouse models and approaches
Additional ongoing efforts to develop mouse models for studying 
SARS-CoV-2 infection involve mice humanized with human ACE2 and 
human haematopoiesis, or Collaborative Cross mice. Severely immuno-
deficient mice transplanted with human immune cells have widely been 
used to study human-specific viral infections24,25, and the combination 
Table 1 | SARS-CoV-2 infection in humans and in animal 
models
Trait Organism
Virus replication
Upper respiratory tract Humans, mice, ferrets, non-human 
primates, mink, cats and bats
Lower respiratory tract Humans, mice, hamsters, ferrets and 
non-human primates
Other organs Humans (GI tract, CNS and kidney), 
hACE2 mice (CNS), hamsters, ferrets and 
non-human primates (GI tract)
Clinical signs
Fever Human and ferrets
Nasal discharge Humans and ferrets
Laboured breathing Humans and hamsters
Pneumonia
Bilateral lung involvement Humans, hamsters and non-human 
primates
Ground-glass opacities Humans, hamsters and non-human 
primates
Focal oedema and inflammation Humans, hamsters, ferrets and non-human 
primates
ARDS Humans
Transmission Humans, hamsters, ferrets, cats and bats
Immunology
Seroconversion Humans, mice, hamsters, ferrets, 
non-human primates and bats
Neutralizing antibody titres Humans, mice, hamsters, ferrets and 
non-human primates
T cell immunity Humans, mice, ferrets and non-human 
primates
Pro-inflammatory cytokines Humans, mice and non-human primates
Demographics
More severe disease in males Humans, hamsters
More severe disease in older 
individuals
Humans, hamsters and non-human 
primates
Comparison of SARS-CoV-2 infection in animal models and humans. CNS, central nervous 
system; GI, gastrointestinal; ARDS, acute respiratory distress syndrome.
of human immune system and ACE2 expression could help to further 
explore the efficacy of vaccines and therapies—in particular, those 
that modulate human immune cells. Similarly, previous studies have 
shown that the Collaborative Cross model of genetic diversity (a panel 
of recombinant inbred mice with expanded susceptibility to viruses 
that normally do not cause disease in laboratory mice) can be used to 
enhance virus disease susceptibility; however, infection remains heav-
ily dependent on a functional entry receptor26,27. Collaborative Cross 
mice were previously used with mouse-adapted SARS-CoV to identify 
mechanisms of pathogenesis and genetic loci that determine suscep-
tibility28. Presumably, Collaborative Cross studies could enable the 
exploration of an expanded range of SARS-CoV-2 phenotypes in mice 
that potentially better recapitulates human disease, as mouse-adapted 
strains become available.
In summary, several mouse models of mild and severe COVID-19 have 
been described or are under development. All of these models will be 
useful for the evaluation of vaccines and antiviral agents, and some 
share features with the human disease. At present, no mouse model 
recapitulates all aspects of COVID-19 in humans, especially the unusual 
features such as the pulmonary vascular disease and hyperinflam-
matory syndromes observed in adults and children, respectively29,30. 
However, continued refinement may result in models even for these 
aspects of the human disease.
Syrian hamster model
Syrian hamsters (Mesocricetus auratus) are small mammals that have 
been used as models for infection with respiratory viruses, includ-
ing SARS-CoV, influenza virus and adenovirus31–34. In silico compari-
son of the ACE2 sequence of humans—known to interact with the 
receptor-binding domain of the SARS-CoV-2 spike glycoprotein—with 
that of hamsters35 suggested that Syrian hamsters might be susceptible 
to infection with SARS-CoV-2. Upon experimental intranasal infec-
tion, Syrian hamsters show mild-to-moderate disease with progressive 
weight loss that starts very early after infection (days 1–2 after inocu-
lation). All hamsters that have been challenged by different groups 
and with different SARS-CoV-2 isolates consistently showed signs of 
respiratory distress, including laboured breathing35,36. Additional signs 
of morbidity included lethargy, ruffled fur and a hunched posture35. 
After two weeks of infection, hamsters typically recovered. Of particular 
interest is the fact that infection with SARS-CoV-2 in hamsters reflects 
some of the demographic differences of COVID-19 in humans. Thus, 
aged hamsters and male hamsters seem to develop a more severe dis-
ease than young and female hamsters, respectively37,38.
In hamsters, SARS-CoV-2 infection is associated with high levels of 
virus replication and histopathological evidence of disease, which 
included ground-glass opacities and evidence of gas in the cavity sur-
rounding the lungs38. These findings are similar to those previously 
reported for SARS-CoV infection in this model32. Viral RNA is readily 
detected in the respiratory tract and other tissues (such as the small 
intestine), which could be useful for the evaluation of therapeutic 
agents and vaccines. Virus transmission to cage-mates has also been 
observed35, which suggests that hamsters may be useful in transmis-
sion studies. Histologically, inflammatory infiltrates with abundant 
expression of viral antigen and apoptosis were observed in the upper 
and lower respiratory tract, starting at 2 days after infection, being at 
their most severe at 4 days after infection and resolving at 14 days after 
infection. Among the non-respiratory-tract tissues, only the intestine 
demonstrated expression of viral antigen in association with severe 
epithelial-cell necrosis, damaged and deformed intestinal villi, and 
increased infiltration of the lamina propria by mononuclear cells. 
Lung disease was also demonstrated by computed tomography. 
High-resolution micro-computed tomography scans showed airway 
dilation and substantial consolidations in the lungs of infected ham-
sters36. A quantitative analysis revealed an increase in the non-aerated 
lung volume in these hamsters. This method thus allows quantitative 
monitoring of disease without the need to euthanize the animals.
Expression of chemokines and cytokines in the lungs of hamsters 
peaked at four days after infection, and then gradually resolved by seven 
days after infection. Interferon-γ, and pro-inflammatory chemokines 
and cytokines, were potently induced at two and four days after infec-
tion, respectively, and dropped to the baseline level at seven days after 
infection. SARS-CoV-2-induced lung pathology in hamsters appears 
to be driven by immune pathology, as lung injury at four days after 
infection is markedly reduced in STAT2-knockout hamsters whereas 
viral loads are massively increased and viral RNA is disseminated 
in several peripheral tissues36. Serum neutralizing antibodies were 
detected as early as seven days after infection. Passive immunization 
of naive hamsters with samples of this convalescent serum resulted in 
significantly reduced viral loads in the respiratory tract, but no obvious 
improvement in clinical signs and histological changes. Furthermore, 
SARS-CoV-2 can be transmitted between hamsters via close contact 
and non-contact routes35,39. Transmission via fomites was possible, 
but not efficient39.
Because studies in hamsters can be completed quickly and in a 
cost-effective manner, there is an increasing interest in the use of this 
model for screening of therapeutic agents. Limited or no efficacy has 
been demonstrated for the repurposed drugs hydroxychloroquine 
(with or without azithromycin) and favipiravir—although high doses 
of favipiravir did reduce infectious virus titres in the lungs of infected 
hamsters40,41. A YF17D-vectored SARS-CoV-2 vaccine candidate con-
ferred efficient protection against SARS-CoV-2 challenge in hamsters42. 
Adoptive transfer of SARS-CoV-2 neutralizing antibodies protected 
hamsters from SARS-CoV-2-induced disease43. A caveat of hamster 
models is the lack of research tools for this species—these remain scarce 
when compared (for example) with those available for mice.
Ferret models
Ferrets (Mustela putorius furo) have been shown to be a highly valu-
able model for testing the pathogenicity and transmission of human 
respiratory viruses, including influenza virus and respiratory syncytial 
virus44,45. It is thus not surprising that the ferret model has been inves-
tigated for studies of the pathogenesis of COVID-19 and SARS-CoV-2 
transmission. Despite the use of different isolates of SARS-CoV-2, the 
results have been notably consistent across all laboratories.
Following mucosal exposure to SARS-CoV-2, clinical alterations in 
ferrets are undetectable or mild and may include lethargy, nasal dis-
charge, wheezing, oropharyngeal build-up of mucus, sneezing and 
loose stools46. Ferrets infected by small-particle aerosols had similar 
disease, albeit at 100-fold lower doses. Peaks of elevated body tem-
peratures have been observed in some studies, although alterations 
in body weight are absent or minimal. Minor alterations in haema-
tological parameters, such as mild lymphopenia and neutrophilia, 
have also been observed. Shedding of SARS-CoV-2 virus is observed 
in nasal and oropharyngeal swabs47–50. As with Syrian hamsters, virus 
replication is detected in the upper respiratory tract very early after 
infection (day 2) and is detectable during two weeks of infection. Virus 
replication in ferrets appears to be restricted to the respiratory and 
gastrointestinal tracts.
The predominant histopathology findings in SARS-CoV-2-infected 
ferrets euthanized at the peak of virus replication include inflammation 
within alveolar spaces and perivascular mononuclear inflammation. In 
addition, in the larger airways of these ferrets, bronchial submucosal 
foci with eosinophilic material and collagen fragments (suggestive 
of collagen degeneration) were observed. Microscopic findings in 
euthanized ferrets were mild, and included broncho-alveolar or alveolar 
inflammation.
Ferrets also are able to transmit virus efficiently to uninfected fer-
rets in experimental settings. Efficient transmission occurred from 
experimentally infected ferrets to naive cage-mates; transmission 
from exposed ferrets to companion ferrets that were separated by 
steel grids did occur, but was not efficient49,51. These studies indicated 
that airborne transmission of SARS-CoV-2 can occur, and suggested 
that the ferret model may be useful for further transmission studies.
To date, studies performed in ferrets strongly indicate that 
experimental SARS-CoV-2 infection results in a predominantly 
upper-respiratory-tract infection in these animals. These findings make 
the ferret model well-suited to testing the efficacy of mucosal vaccines 
and therapeutic agents that aim to prevent upper airway infection  
and/or transmission.
Non-human-primate models
Non-human-primate models have been explored for COVID-19 in rhesus 
macaques (Macaca mulatta), cynomolgus macaques (Macaca fas-
cicularis) and African green monkeys (Chlorocebus aethiops). Studies 
from several laboratories have shown high levels of viral replication for 
7–14 days (including both viral RNA and infectious virus) in both the 
upper and lower respiratory tract, pathological features of viral pneu-
monia and the variable induction of mild clinical disease52–55. Only mild 
clinical disease has been reported in non-human primates, and insuf-
ficient comparable data exist at this time to determine whether there 
is more clinical disease in rhesus macaques, cynomolgus macaques or 
African green monkeys. The induction of innate, humoral and cellular 
immune responses as well as robust protection against rechallenge 
has also been reported, which demonstrates the induction of natural 
protective immunity in this model54. Non-human primates inoculated 
via multiroute mucosal, intrabronchial and aerosol exposure showed 
radiographic abnormalities (by chest X-ray, computed tomography 
scan or fluorodeoxyglucose positron emission tomography scan) 
within 2 days, which tended to resolve by 11–15 days after infection. 
Evidence of the shedding of live virus has been found in both the 
respiratory and gastrointestinal tracts. In addition, haematological 
changes—with evidence of T cell activation, mild lymphopenia and 
neutrophilia—have been observed in infected non-human primates.
In humans, infection with SARS-CoV-2 in older individuals 
is associated with an adverse clinical outcome. Currently, two 
non-human-primate studies in rhesus and cynomolgus macaques have 
focused on the effect of age on infection with SARS-CoV-253,56. Both 
studies showed that aged macaques shed virus from nose and throat 
for longer periods of time that do young adult macaques. Higher viral 
loads were also detected in lung tissue of aged rhesus macaques. In 
addition, advanced age in rhesus macaques was also associated with 
an increased number of radiological and histopathological changes. 
These studies highlight the importance of including age in the selec-
tion criteria of animals, as testing treatment options for severe disease 
require animal models that recapitulate the disease as seen in humans.
Recent studies have reported the immunogenicity and protective 
efficacy of several candidates for a COVID-19 vaccine in the rhesus 
macaque model57–61. A concern is that different challenge stocks were 
used in each of these studies, and may have contributed to the con-
siderable variation in magnitude, consistency and duration of viral 
replication observed in the control groups in some of these studies. 
Standardized and sequenced challenge stocks and protocols will be 
needed to compare vaccine efficacy in non-human primates. Despite 
this caveat, the vaccines tested so far have induced binding and neutral-
izing antibodies and have resulted in substantial reductions of viral rep-
lication in the lower respiratory tract, and—to a lesser extent—the upper 
respiratory tract, following challenge with SARS-CoV-2. These findings 
raise the possibility that vaccines may be more effective at blocking 
disease of the lower respiratory tract than of the upper respiratory 
tract. Anamnestic immune responses were observed in some studies, 
but not others, following challenge, which suggests that protection 
is often mediated by rapid immunological control but that complete 
protection may also be possible. Vaccine-elicited neutralizing-antibody 
titres also correlated with protective efficacy57.
Additional animal models
In addition to animal models that are more commonly used in infec-
tious disease research, recent studies have characterized infection with 
SARS-CoV-2 in other animals. Here we highlight these recent findings, 
which may have implications for virus ecology and the evolution of 
the current pandemic.
Mink
The mink (Neovison vison), which is a member of the Mustelidae, has 
previously been shown to be susceptible to infection with SARS-CoV62; 
mink lung epithelial cells and lung-derived cells could also be infected 
with SARS-CoV63. Mink are also naturally susceptible to infection with 
SARS-CoV-2. In the Netherlands, an infection of mink with SARS-CoV-2 
on two breeding farms was detected at the end of April 2020—most 
probably as a result of contact with a farm worker who was infected 
with SARS-CoV-264. At the time of writing, 41 additional mink farms have 
confirmed infections with SARS-CoV-2 and thousands of mink have 
been culled in the Netherlands and Spain. In contrast to ferrets, mink 
displayed moderate respiratory signs that included laboured breath-
ing, and some mink died as a result of infection. SARS-CoV-2 virus was 
found in the majority of throat and rectal swabs collected from dead 
mink from both farms. Similar to ferrets, the viral loads in mink were 
higher in the throat swabs than in the rectal swabs. Although mink may 
represent a suitable model for moderate-to-severe COVID-19, they are 
difficult to handle under laboratory conditions.
Cats
Three experiments have demonstrated that domestic cats (Felis catus) 
are highly susceptible to infection with SARS-CoV-2 and are able to 
transmit the virus to naive cats50,65,66. For example, the inoculation of 
the SARS-CoV-2 isolate CTan-H into juvenile (70–100 days old) and 
subadult cats (6–9 months old) through the intranasal route resulted 
in virus replication in the upper and lower respiratory tract, as well as 
in the gastrointestinal tract. Both experimentally infected and contact 
cats seroconverted. At necropsy, interstitial pneumonia, loss of cilia and 
epithelial necrosis, as well as inflammation in nasal turbinates and tra-
chea, were observed. The authors did not describe clinical signs in any of 
the infected cats, except that 2 juvenile cats (out of 10 in total) died (on 
day 3 and day 13 after infection)50. Virus antigen was found in epithelial 
cells of the nasal turbinates, necrotic debris in the tonsil, submucosal 
glands of the trachea and enterocytes of the small intestine. SARS-CoV-2 
transmission by droplets was also demonstrated50. Although cats may 
represent a suitable model for asymptomatic-to-moderate COVID-19, 
before they are used as such we should be sure that the benefits out-
weigh the concerns of using companion animals for research; further-
more, cats are difficult to handle in biosafety level-3 containment, and 
are not a standard animal model. However, owing to their close contact 
to humans, additional studies—for example, on environmental con-
tamination (cages, beds, food and water bowls, litterboxes and so on) 
or on transmission efficiency—may be important to inform veterinary 
and public health authorities about the risk of cats as intermediate 
hosts or virus carriers at the interface between SARS-CoV-2, humans 
and animals.
Dogs
Dogs (Canis lupus familiaris) have been shown to be susceptible to 
SARS-CoV-2, but to a very mild degree. Two experiments have so far 
been published in this species, which conclude that dogs have a low sus-
ceptibility to infection with SARS-CoV-250,66. The susceptibility of both 
cats and dogs to natural and experimental infection with SARS-CoV-2 
strongly suggests that antibody testing in these species could be a 
useful tool for epidemiological studies, in particular in areas with high 
density of cases of COVID-19 in humans.
Pigs
In silico data suggested that swine ACE2 should bind the spike protein 
of SARS-CoV-2. However, several experimental infections performed in 
pigs (Sus scrofa domesticus) by different research groups indicate that 
this species is not susceptible to infection with SARS-CoV-2 in vivo49,50. 
No clinical signs and no clear evidence of virus replication have been 
observed in pigs. Therefore, pigs do not appear to represent a suit-
able animal model for COVID-19. Conversely, previous studies have 
reported infection with SARS-CoV in pigs67. Experimental infection 
of pigs with SARS-CoV resulted in the detection of viral RNA in the 
blood and seroconversion, but not in clinical signs or virus isolation, 
which ruled out pigs as amplifying hosts for SARS-CoV68. By contrast, 
infection with another bat betacoronavirus—known as swine acute 
diarrhoea syndrome coronavirus (SADS-CoV)—has been demonstrated 
in swine69. Therefore, owing to their importance as livestock and the 
enormous global number of pigs, it may be important for future stud-
ies to address the putative susceptibility of additional pig breeds to 
infection with SARS-CoV-2.
Chickens and ducks
At least one in silico study using the informational spectrum methodol-
ogy proposed chicken as an animal species that is potential susceptible 
to infection with SARS-CoV-270. However, the limited experimental 
studies performed so far have suggested that chickens—including 
embryonated chicken eggs—and ducks are not susceptible to infection 
with SARS-CoV-249,50,71. Neither chickens nor ducks appear to represent 
suitable animal models for studies of SARS-CoV-2 infection. These 
findings are similar to those previously reported for infection with 
SARS-CoV, in which experimental inoculation of different bird species 
with SARS-CoV (including chickens) resulted in neither replication nor 
seroconversion72.
Fruit bats
Pre-pandemic studies that assessed the potential emergence of 
SARS-like coronaviruses in bats indicated that some of these viruses 
were able to use several orthologues of human ACE2 for docking and 
entry73,74. These studies underscored the importance of coronavirus sur-
veillance studies in bats, as these animals are regarded as the natural res-
ervoir of many coronaviruses—including SARS-CoV and SARS-CoV-275,76. 
The intranasal inoculation of fruit bats (Rousettus aegyptiacus) with 
SARS-CoV-2 resulted in efficient replication in the upper respiratory 
tract and seroconversion in seven out of nine of the bats. Transmis-
sion occurred to one out of three direct-contact animals. Clinical signs 
were absent, but rhinitis could be detected by immunohistology49. 
Conversely, previous studies showed that a SARS-like coronavirus 
did not replicate in fruit bats after experimental inoculation77. These 
findings suggest that, although Rousettus bats are not the original 
reservoir species of SARS-CoV-2, experimental infection of these fruit 
bats could help to model the physiopathology of the virus in its host.
Preclinical alternatives to animal models
Historically, animal alternatives for studying respiratory viruses have 
involved in vitro approaches such as cell lines (for example, Vero, A549 
and MDCK cell lines) or primary-tissue-derived human cells in conven-
tional cell culture. However, over the past decade, advances in engineer-
ing, cell biology and microfabrication have come together to enable the 
development of new human-cell-based alternatives to animal models. 
In this regard, micro-engineered organs-on-chips and lung organoids 
have been shown to support key hallmarks of the cytopathology and 
inflammatory responses observed in human airways after infection with 
SARS-CoV-2 and have served to facilitate the study of human disease 
pathogenesis, test candidate COVID-19 therapeutic agents and expedite 
drug repurposing78,79.
Perspectives
Since SARS-CoV-2 emerged in the human population in late 2019, it 
has spread via human-to-human transmission to most countries in the 
world, leading to a coronavirus pandemic of an unprecedented scale. 
Under the umbrella of the WHO, the WHO-COM is fostering the develop-
ment of animal models for COVID-19 through international exchange 
of protocols, unpublished data and ideas across many laboratories in 
the world. As discussed in this Review, a number of studies have been 
conducted—many of them by members of the WHO-COM—that indicate 
that some of the animal models support viral replication.
A study80 based on the three-dimensional X-ray structure of 
SARS-CoV-2 spike protein bound to human ACE2 has discussed the 
variance observed between 19 different animal species, as well as within 
3 colonies of the same species of bat from different provinces within 
China. This analysis noted that many predicted affinities of the spike 
protein for the ACE2 receptor (especially those of dog and pig) did not 
match the relative natural resistance of the corresponding species to 
SARS-CoV-2. This was proposed to be due to differences between spe-
cies in the levels of ACE2 expression in the respiratory epithelium80. 
Similarly, a recent study aimed to predict the host range of SARS-CoV-2 
through a comparative structural analysis of ACE2 in more than 400 ver-
tebrates. These data show discrepancies between the predicted suscep-
tibilities to infection and those experimentally observed; ferrets, for 
example, were predicted to have a very low susceptibility to infection81. 
These data suggest that susceptibility to infection may be a function 
of several factors, including genetic ACE2 composition, organ-specific 
ACE2 expression and other host factors (such as additional receptors 
and host immune responses).
One immediate goal of the WHO-COM group is to evaluate whether 
mimicking human comorbidities, co-infections or the immune senes-
cence associated with age in animal models may result in more-severe 
disease phenotypes. The existing animal models have also been valu-
able for testing vaccines and therapeutic agents. Several vaccine can-
didates have shown protection in rhesus macaques57–61, and both the 
cynomolgus and rhesus macaque models have been useful for the 
testing of therapeutic agents82. In future studies, it will be important to 
define key outcome measures that would allow comparison between 
candidate interventions in animal models and humans. Many of the 
pathogenesis studies described in this Review have also highlighted 
an important caveat in COVID-19 research, which are the methods 
used to measure virus replication. The group found that viral RNA 
or genome copy numbers measured by quantitative PCR assays were 
three-to-four orders of magnitude higher than infectious virus titres 
measured by cell culture assays, and thus combining cytopathogenic 
effect or plaque assays with the PCR-based quantification of viral RNA 
is a prudent approach to evaluating virus shedding and the potential 
for virus transmission. Standardization of these measurements will be 
important for the future evaluation of vaccines and therapeutic agents.
There have been concerns that coronaviruses might pose 
a risk of vaccine-associated enhanced respiratory disease or 
antibody-dependent enhancement of virus entry and replication in cells 
bearing the Fc receptor83. These types of syndrome have been linked to 
vaccines that induced substantial levels of non-neutralizing antibod-
ies or responses biased toward type-2 helper CD4 T cells. Therefore, 
evaluating the relative potency of neutralizing activity to overall bind-
ing antibody and obtaining evidence for responses biased toward the 
CD4 subset of T cells through cytokine production or antibody-subtype 
response patterns would be informative. To ensure such models are 
able to provide these readouts, it is important to attempt to induce 
vaccine-associated enhanced respiratory disease in models of COVID-19 
challenge using suboptimal doses of candidate vaccines or antigenic 
preparations with the goal of inducing the required detrimental 
immune profile and associated lung pathology.
Outlook
There are a number of small and large animal models that investigators can 
use to explore important aspects of COVID-19, including pathology, trans-
mission and host responses to SARS-CoV-2, as well as to help to establish 
the safety and efficacy of potential therapeutic agents and vaccines. Future 
studies will need to standardize challenge stocks, assays and protocols to 
allow comparisons of different candidate interventions. Animal models 
are needed to assess vaccine-associated enhanced respiratory disease, and 
the establishment of a positive control for this disease will be important.
Continued refinement and development of animal models for COVID-
19 will contribute to the development of vaccines, therapeutic agents 
and other countermeasures. Large-scale clinical trials are currently 
underway to test multiple candidate preventative and therapeutic 
interventions in humans. The outcomes of these clinical-efficacy trials 
will allow an unprecedented opportunity for the back-validation and 
refinement of these animal models.
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